MINODIAB Tablet Ref.[27643] Active ingredients: Glipizide

Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Product name and form

Minodiab 5 mg Tablets.

Pharmaceutical Form
Tablet. White biconvex tablets scored on both sides. The score line is not intended for breaking the tablet.

Qualitative and quantitative composition

5 mg Glipizide.

Excipient with known effect:

Each tablet contains 153 mg lactose monohydrate.

For the full list of excipients, see section 6.1.

Active Ingredient	Description
Glipizide	Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue.

List of Excipients
Microcrystalline cellulose Starch Stearic acid Lactose

Pack sizes and marketing

Blister strips containing 28 or 60 tablets in a carton.

Not all pack sizes may be marketed.

Marketing authorization holder

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Marketing authorization dates and numbers

PL 00057/1016

Date of first authorisation: 4^th September 2012
Date of latest renewal: 5^th April 2002

Drugs

Drug	Countries
MINODIAB	Spain, Mexico, United Kingdom

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.